NCT03847350 (BENEFIT) is a clinical trial in Essential Hypertension, sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd.

Who is sponsoring NCT03847350?

NCT03847350 is sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd.

What condition does NCT03847350 study?

NCT03847350 studies Essential Hypertension.

Is NCT03847350 still recruiting?

NCT03847350 is currently completed. Last updated 20 February 2019.

Last reviewed 2019-02-20 · How we verify

NCT03847350: BENEFIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension

Completed Last updated 20 February 2019

What this trial tests

trial in Essential Hypertension in 3,250 participants. Completed in 23 March 2017.

Timeline

1 July 2015

Primary endpoint
23 March 2017

23 March 2017

Quick facts

Lead sponsor	A.Menarini Asia-Pacific Holdings Pte Ltd
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,250
Start date	1 July 2015
Primary completion	23 March 2017
Estimated completion	23 March 2017
Sites	1 location across South Korea

Conditions studied

Essential Hypertension — all drugs for Essential Hypertension →

Sponsor

A.Menarini Asia-Pacific Holdings Pte Ltd — full company profile →

Who can join

19 and older, any sex, with Essential Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is: To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential hypertension (with or without co-morbidities) after 12 weeks and 24 weeks.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study.
Shin J, Choi YJ, Hong GR, Jeon DW, et al · · 2020 · cited 4× · PMID 31693535 · DOI 10.1097/hjh.0000000000002296
Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study.
Cho KI, Jeon DW, Ahn HS, Jin DK, et al · · 2021 · cited 3× · PMID 33722290 · DOI 10.1186/s40885-021-00165-3
Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study.
Shin J, Cha DH, Bae WH, Jung IH, et al · · 2025 · cited 1× · PMID 40083595 · DOI 10.5646/ch.2025.31.e8

Verify or expand the search:

Other recruiting trials for Essential Hypertension

Currently open trials in the same condition.

NCT07282145 — Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers · Phase 1 · recruiting
NCT06778239 — Childhood-Onset Essential Hypertension Natural History Study · recruiting
NCT07051811 — To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension · NA · recruiting
NCT06643819 — Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A · Phase 3 · recruiting
NCT05880056 — Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian P · Phase 4 · recruiting

Other A.Menarini Asia-Pacific Holdings Pte Ltd trials

Trials by the same sponsor.

NCT03633760 — Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese Population · Phase 1 · unknown
NCT03895762 — Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03847350 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by A.Menarini Asia-Pacific Holdings Pte Ltd
Last refreshed: 20 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03847350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing